Affimed - Rega Nyata Tumbas Perusahaan Kanthi Wutuh AFMD

Affimed (AFMD) focuses on independent oncology drug trials, collaborating exclusively with research centers. The historical price action of the Separate Enterprise Value currently stands at . While the business develops cancer-fighting treatments, the lack of recurring sales makes its financial stability dependent on trial outcomes. Meanwhile, external risks and sanctions could disrupt raw material supplies and complicate patent protection.

The capitalization of Affimed (AFMD), bolstered by payments from Roche for the development of cancer immunotherapy, directly impacts the overall business value. By summing the market value of shares and net debt, this indicator determines the actual acquisition price of the issuer, allowing for an assessment of the risk of overpaying for biopharmaceutical assets over time through the evolution of the company's enterprise value.